Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial

By O’Malley F.   Chia S.   Tu D.   Shepherd L.   Levine M.   Huntsman D.   Bramwell V.   Andrulis I.   Pritchard K.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 2, 2011-07 ,pp. : 401-409

Springer Publishing Company

Access to resources Recommend Favorite

A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

By Cigler T.  

Breast Cancer Research and Treatment, Vol. 126, Iss. 2, 2011-04 ,pp. : 453-461

Springer Publishing Company

Access to resources Recommend Favorite

The FACE Trial: Letrozole or Anastrozole as Initial Adjuvant Therapy?

By Jonat Walter   Mundhenke Christoph  

Cancer Investigation, Vol. 25, Iss. 1, 2007-01 ,pp. : 14-18

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast Cancer

By Ouagari Khalid   Karnon Jon   Delea Thomas   Talbot Willena   Brandman Jane  

Breast Cancer Research and Treatment, Vol. 101, Iss. 1, 2007-01 ,pp. : 37-49

Springer Publishing Company

Access to resources Recommend Favorite

Placebo-Controlled Trial of Indole-3-Carbinol in the Treatment of CIN

By Bell M.C.   Crowley-Nowick P.   Bradlow H.L.   Sepkovic D.W.   Schmidt-Grimminger D.   Howell P.   Mayeaux E.J.   Tucker A.   Turbat-Herrera E.A.   Mathis J.M.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 123-129

Elsevier

Access to resources Recommend Favorite